The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study

This publication has 32 references indexed in Scilit:

• Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
  European Journal of Cancer, 2021
• The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
  European Journal of Cancer, 2021
• Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer
  Current Oncology Reports, 2019
• Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation
  Bone, 2019
• Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database
  European Urology Oncology, 2018
• Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
  Clinical Genitourinary Cancer, 2018
• Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts
  Cancer, 2018
• Integrative Clinical Genomics of Advanced Prostate Cancer
  Cell, 2015
• Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
  European Urology, 2015
• Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review
  European Urology Supplements, 2010